Brawn Biotech

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE899B01015
  • NSEID:
  • BSEID: 530207
INR
19.12
-0.88 (-4.4%)
BSENSE

Dec 05

BSE+NSE Vol: 1

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Cr
Standalone - Balance Sheet Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Balance Sheet Analysis Highlights
stock-summary

Borrowings

No Borrowings in the last few periods;

stock-summary

Other Long Term Liabilities

No Other Long Term Liabilities in the last few periods;

stock-summary

Fixed Assets

YoY Growth in year ended Mar 2025 is 39.39% vs -10.81% in Mar 2024

stock-summary

Investments

No Investments in the last few periods;

stock-summary

Current Assets

YoY Growth in year ended Mar 2025 is 33.18% vs -1.94% in Mar 2024

Compare Balance Sheet Results of Brawn Biotech
Markets Mojo
Figures in Cr
Standalone - Balance Sheet Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
EQUITY AND LIABILITIES
Share Capital
3.00
4.84
-1.84
-38.02%
Share Warrants & Outstandings
Total Reserve
0.36
1.67
-1.31
-78.44%
Shareholder's Funds
3.36
7.13
-3.77
-52.88%
Minority Interest
0.00
0.00
0.00
0.00%
Long-Term Borrowings
0.00
0.23
-0.23
-100.00%
Secured Loans
0.00
0.00
0.00
0.00%
Unsecured Loans
0.00
0.23
-0.23
-100.00%
Deferred Tax Assets / Liabilities
-0.51
0.01
-0.52
-5,200.00%
Other Long Term Liabilities
0.00
0.00
0.00
0.00%
Long Term Trade Payables
7.71
0.00
7.71
0.00%
Long Term Provisions
0.09
0.00
0.09
0.00%
Total Non-Current Liabilities
7.29
0.24
7.05
2,937.50%
Current Liabilities
Trade Payables
8.24
0.28
7.96
2,842.86%
Other Current Liabilities
1.01
0.14
0.87
621.43%
Short Term Borrowings
0.00
1.19
-1.19
-100.00%
Short Term Provisions
0.08
0.00
0.08
0.00%
Total Current Liabilities
9.33
1.60
7.73
483.12%
Total Liabilities
19.97
8.97
11.00
122.63%
ASSETS
Non-Current Assets
0.00
0.00
0.00
0.00%
Gross Block
1.02
1.47
-0.45
-30.61%
Less: Accumulated Depreciation
0.56
0.80
-0.24
-30.00%
Less : Impairment of Assets
0.00
0.00
0.00
0.00%
Net Block
0.46
0.66
-0.20
-30.30%
Lease Adjustment
0.00
0.00
0.00
0.00%
Capital Work in Progress
0.00
0.00
0.00
0.00%
Intangible assets under development
0.00
0.00
0.00
0.00%
Pre-operative Expenses pending
0.00
0.00
0.00
0.00%
Assets in transit
0.00
0.00
0.00
0.00%
Non Current Investments
0.00
0.00
0.00
0.00%
Long Term Loans & Advances
0.00
0.00
0.00
0.00%
Other Non Current Assets
2.01
1.44
0.57
39.58%
Total Non-Current Assets
2.47
2.11
0.36
17.06%
Current Assets Loans & Advances
Current Investments
0.00
0.00
0.00
0.00%
Inventories
10.47
1.18
9.29
787.29%
Sundry Debtors
3.41
0.91
2.50
274.73%
Cash and Bank
0.20
0.30
-0.10
-33.33%
Other Current Assets
0.20
0.00
0.20
0.00%
Short Term Loans and Advances
3.22
4.47
-1.25
-27.96%
Total Current Assets
17.50
6.87
10.63
154.73%
Net Current Assets (Including Current Investments)
8.17
5.26
2.91
55.32%
Total Current Assets Excluding Current Investments
17.50
6.87
10.63
154.73%
Miscellaneous Expenses not written off
0.00
0.00
0.00
0.00%
Total Assets
19.97
8.97
11.00
122.63%
Contingent Liabilities
0.00
0.00
0.00
0.00%
Total Debt
0.00
1.42
-1.42
-100.00%
Book Value per share (adjusted)
11.21
13.46
-2.25
-16.72%
Annual - Borrowings
Markets Mojo
No Borrowings in the last few periods
stock-summary

No Borrowings in the last few periods;

Annual - Other Long Term Liabilities
Markets Mojo
No Other Long Term Liabilities in the last few periods
stock-summary

No Other Long Term Liabilities in the last few periods;

Annual - Fixed Assets
Fixed Assets 0.46 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 39.39% vs -10.81% in Mar 2024

Annual - Investments
Markets Mojo
No Investments in the last few periods
stock-summary

No Investments in the last few periods;

Annual - Current Assets
Current Assets 17.50 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 33.18% vs -1.94% in Mar 2024